moxifloxacin has been researched along with rifapentine in 36 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (rifapentine) | Trials (rifapentine) | Recent Studies (post-2010) (rifapentine) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 404 | 77 | 242 |
| Protein | Taxonomy | moxifloxacin (IC50) | rifapentine (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 9.91 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.78) | 18.2507 |
| 2000's | 14 (38.89) | 29.6817 |
| 2010's | 14 (38.89) | 24.3611 |
| 2020's | 7 (19.44) | 2.80 |
| Authors | Studies |
|---|---|
| Bitting, C; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Woolhiser, L | 1 |
| Chaisson, RE; Dooley, K; Dorman, SE; Flexner, C; Hackman, J; Nuermberger, E; Peloquin, CA | 1 |
| Aarnoutse, RE; Boeree, MJ; Kibiki, GS; Kisanga, ER; van den Boogaard, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Eliopoulos, GM; Ferraro, MJ; Moellering, RC; Schülin, T; Wennersten, CB | 1 |
| Bentoucha, A; Bonnafous, P; Consigny, S; Grosset, J; Ji, B | 1 |
| Grosset, J; Ji, B | 1 |
| Bentoucha, A; Grosset, J; Ji, B; Lounis, N; O'Brien, RJ; Roscigno, G; Truffot-Pernot, C; Vernon, A | 1 |
| Au-Yeang, C; Chan, CY; Cheng, AF; Leung, CC; Yew, WW | 1 |
| Bishai, WR; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, K | 2 |
| Bishai, WR; Grosset, JH; Nuermberger, E; Rosenthal, I; Tyagi, S; Williams, KN | 1 |
| Chauffour, A; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N | 1 |
| Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M | 1 |
| Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M | 1 |
| Daley, CL | 1 |
| Andries, K; Gevers, T; Lounis, N | 1 |
| Denti, P; Geldenhuys, H; Hanekom, W; Harrison, T; Hatherill, M; Jindani, A; McIlleron, HM; Meredith, S; Simonsson, US; van As, D; Wiesner, L; Zvada, SP | 1 |
| Schaberg, T | 1 |
| Cailleaux-Cezar, M; Chaisson, RE; Conde, MB; Efron, A; Luiz, RR; Mexas, F | 1 |
| Bateson, AL; Butcher, PD; Charalambous, S; Churchyard, GJ; Clouting, HE; Coleman, D; Geldenhuys, H; Harrison, TS; Hatherill, M; Jindani, A; Magweta, L; McHugh, TD; McIlleron, HM; Mitchison, DA; Mungofa, S; Nunn, AJ; Nyirenda, S; Phillips, PP; Shah, NA; Shepherd, J; van Dijk, JH; Zizhou, S; Zvada, SP | 1 |
| Mizrahi, V; Warner, DF | 1 |
| Armstrong, DT; Barnes, GL; Cavalcante, SC; Chaisson, RE; Cohn, S; Conde, MB; Dalcolmo, M; Dooley, KE; Dorman, SE; Duarte, RS; Durovni, B; Efron, A; Loredo, C; Marzinke, MA; Mello, FC; Moulton, LH; Rolla, V; Savic, RM | 1 |
| Lu, JM; Sha, W; Xiao, HP; Yang, H; Zhang, LL; Zhang, Q | 1 |
| Aubry, A; Chauffour, A; Jarlier, V; Robert, J; Veziris, N | 1 |
| Essack, S; McIlleron, H; Naidoo, A; Naidoo, K; Padayatchi, N | 1 |
| Arriens, S; Ford, L; Hoerauf, A; Hübner, MP; Klarmann-Schulz, U; Koschel, M; Martin, C; Pfarr, KM; Specht, S; Sternberg, S; Taylor, MJ | 1 |
| Bax, HI; de Knegt, GJ; de Steenwinkel, JEM; Mourik, BC; Simonsson, USH; Svensson, RJ; Verbon, A | 1 |
| Bozeman, L; Burman, WJ; Chaisson, RE; Chang, KC; Chen, M; Cotton, M; Dooley, KE; Dorman, SE; Engle, M; Feng, PJ; Fletcher, CV; Goldberg, SV; Ha, P; Heilig, CM; Johnson, JL; Kurbatova, EV; Lessem, E; Metchock, B; Miro, JM; Nahid, P; Nhung, NV; Pettit, AC; Phillips, PPJ; Podany, AT; Purfield, AE; Robergeau, K; Samaneka, W; Scott, NA; Sizemore, E; Swindells, S; Vernon, A; Weiner, M | 1 |
| Adams, LB; Collins, JH; Hagge, DA; Lahiri, R; Lenz, SM; Ray, NA | 1 |
| Mizrahi, V; Rubin, EJ | 1 |
| Badal-Faesen, S; Bryant, K; Campbell, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Fletcher, CV; Johnson, JL; Kurbatova, EV; Lalloo, U; Martinson, N; Mayanja, H; Mohapi, L; Nahid, P; Pettit, A; Pham, M; Phillips, PPJ; Podany, AT; Samaneka, W; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Whitworth, WC | 1 |
| Allen, L; Carr, W; Goswami, N; Kurbatova, E; Starks, A; Winston, C | 1 |
| Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z | 1 |
| Chen, X; Feng, Z; Ge, S; Li, R; Li, Y; Miao, Y; Peng, Y; Song, L; Sun, F; Wang, X; Zhang, W; Zhang, Y | 1 |
5 review(s) available for moxifloxacin and rifapentine
| Article | Year |
|---|---|
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Mycobacterium tuberculosis; Rifamycins; Tuberculosis | 2009 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Update in tuberculosis 2009.
Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Diarylquinolines; Fluoroquinolones; Humans; Linezolid; Mice; Moxifloxacin; Oxazolidinones; Quinolines; Rifampin; Tuberculosis; Tuberculosis Vaccines; Vitamin D; Vitamins | 2010 |
[Tuberculosis: new treatment options and updated recommendations].
Topics: Antitubercular Agents; Aza Compounds; Cross-Sectional Studies; Diagnosis, Differential; Diarylquinolines; Fluoroquinolones; Germany; Humans; Moxifloxacin; Nitroimidazoles; Oxazoles; Prognosis; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2013 |
A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Interactions; Fluoroquinolones; Humans; Moxifloxacin; Rifampin; Tuberculosis | 2017 |
8 trial(s) available for moxifloxacin and rifapentine
| Article | Year |
|---|---|
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Rifampin; Safety; Tuberculosis, Pulmonary; Young Adult | 2008 |
Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Tuberculosis, Pulmonary | 2012 |
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; HIV Seropositivity; Humans; Isoniazid; Kaplan-Meier Estimate; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult | 2014 |
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Topics: Adult; Antitubercular Agents; Case-Control Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 2016 |
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
Topics: Adolescent; Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Equivalence Trials as Topic; Ethambutol; Female; HIV Infections; Humans; Male; Middle Aged; Moxifloxacin; Rifampin; Tuberculosis, Pulmonary; Young Adult | 2020 |
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Moxifloxacin; Rifampin; Tuberculosis | 2022 |
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Pulmonary | 2023 |
Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.
Topics: Clinical Trials, Phase II as Topic; Humans; Isoniazid; Moxifloxacin; Multicenter Studies as Topic; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis | 2023 |
23 other study(ies) available for moxifloxacin and rifapentine
| Article | Year |
|---|---|
Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
Topics: Animals; Antitubercular Agents; Biological Availability; Interferon-gamma; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridones; Quinolones; Treatment Outcome; Tuberculosis, Pulmonary | 2008 |
Susceptibilities of Legionella spp. to newer antimicrobials in vitro.
Topics: Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Humans; Ketolides; Legionella; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones; Rifampin | 1998 |
Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Foot; Ketolides; Leprostatic Agents; Leprosy; Macrolides; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium leprae; Quinolines; Rifampin; Skin | 2000 |
Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoroquinolones; Leprostatic Agents; Leprosy; Mice; Mice, Inbred Strains; Minocycline; Moxifloxacin; Probability; Quinolines; Rifampin; Treatment Outcome | 2000 |
Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Resistance, Microbial; Female; Fluoroquinolones; Isoniazid; Lung; Mice; Moxifloxacin; Mycobacterium tuberculosis; Organ Size; Quinolines; Rifampin; Spleen; Streptomycin; Survival Rate; Tuberculosis | 2001 |
In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Drug Combinations; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin | 2004 |
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary | 2005 |
Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Spleen; Treatment Outcome; Tuberculosis; Vaccines, DNA | 2005 |
Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
Topics: Animals; Animals, Outbred Strains; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Random Allocation; Rifampin; Survival Rate; Time Factors; Tuberculosis | 2005 |
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Rifampin; Tuberculosis, Pulmonary | 2006 |
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Secondary Prevention; Time Factors; Tuberculosis | 2007 |
Doctors report breakthrough antibiotic treatment for TB.
Topics: Animals; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Fluoroquinolones; Humans; Mice; Moxifloxacin; Quinolines; Rifampin; Treatment Outcome; Tuberculosis | 2007 |
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Recurrence; Rifampin; Time Factors; Treatment Outcome; Tuberculosis | 2008 |
Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis | 2010 |
Understanding and retention of trial-related information among participants in a clinical trial after completing the informed consent process.
Topics: Adult; Antitubercular Agents; Brazil; Comprehension; Developing Countries; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Informed Consent; Male; Middle Aged; Moxifloxacin; Randomized Controlled Trials as Topic; Retention, Psychology; Rifampin; Surveys and Questionnaires; Tuberculosis, Pulmonary | 2014 |
Shortening treatment for tuberculosis--to basics.
Topics: Antitubercular Agents; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Pulmonary | 2014 |
[Determination of in vitro synergy by a checkerboard method when 3 core antimicrobial agents of the retreatment new scheme combined against MDR-MTB and XDR-MTB].
Topics: Aminosalicylic Acids; Antibiotics, Antitubercular; Drug Synergism; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Retreatment; Rifabutin; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
Topics: Animals; Anti-Bacterial Agents; Buruli Ulcer; Clarithromycin; Diarylquinolines; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium ulcerans; Rifampin | 2016 |
Combinations of registered drugs reduce treatment times required to deplete Wolbachia in the Litomosoides sigmodontis mouse model.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Therapy, Combination; Filariasis; Filarioidea; Fluoroquinolones; Mice; Moxifloxacin; Rifampin; Tetracyclines; Time Factors; Treatment Outcome; Wolbachia | 2018 |
Improving treatment outcome assessment in a mouse tuberculosis model.
Topics: Administration, Oral; Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Genotype; Humans; Mice; Mice, Inbred BALB C; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Treatment Outcome; Tuberculosis | 2018 |
Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.
Topics: Animals; Asymptomatic Infections; Bacterial Load; Clarithromycin; Drug Combinations; Leprostatic Agents; Leprosy; Mice; Mice, Nude; Minocycline; Moxifloxacin; Mycobacterium leprae; Post-Exposure Prophylaxis; Rifampin | 2020 |
Shortening the Short Course of Tuberculosis Treatment.
Topics: Humans; Moxifloxacin; Rifampin; Tuberculosis | 2021 |
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
Topics: Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis, Pulmonary; United States | 2022 |